When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Autism spectrum disorder

Last reviewed: 2 Apr 2025
Last updated: 20 Nov 2024

Summary

Definition

History and exam

Key diagnostic factors

  • language delay or regression
  • verbal and nonverbal communication impairment
  • social impairment
  • repetitive, rigid, or stereotyped interests, behavior, or activities
Full details

Other diagnostic factors

  • placid or very irritable as a baby
  • feeding difficulties
  • unusual posturing
  • motor stereotypies
  • sensory interests or difficulties
  • evidence of other neurodevelopmental disorder
  • macrocephaly
Full details

Risk factors

  • male sex
  • positive family history
  • gestational valproate exposure
  • genetic variants
  • karyotype (chromosomal) abnormalities
  • increasing parental age
  • prematurity
Full details

Diagnostic tests

1st tests to order

  • ASD screening tests
  • Childhood Autism Rating Scale (CARS)
  • Modified Checklist for Autism in Toddlers (M-CHAT)
  • Childhood Autism Screening Test (CAST)
Full details

Tests to avoid

  • hair analysis
  • heavy metal urine test and mineral panel
Full details

Tests to consider

  • diagnostic questionnaires (e.g., Autism Diagnostic Interview-Revised [ADI-R]; Developmental, Dimensional, and Diagnostic Interview [3di]; Diagnostic Interview for Social and Communication Disorders [DISCO])
  • Autism Diagnostic Observational Schedule (ADOS)
  • skin examination with Wood lamp
  • genetic testing
  • EEG
  • MRI brain
  • audiology
  • specific testing for genetic disorders (e.g., MECP2 deletion)
Full details

Treatment algorithm

ONGOING

preschool children ages 12 months to 5 years (or equivalent developmental age)

school-age children ages 5 to 18 years (or equivalent developmental age)

adults

Contributors

Authors

Jeremy Parr, MB ChB, MRCPCH, MD

Professor/Honorary Consultant

Population Health Sciences Institute

Newcastle University

Newcastle upon Tyne

UK

Disclosures

JP is a director and shareholder in XRTherapeutics, which offers virtual reality intervention for situation specific anxiety and phobia for people with autism and other conditions. He is named on a patent owned by Third Eye Neurotech and would receive royalties from this, through Newcastle University. JP previously chaired Research Autism's Scientific Advisory Committee; was an expert advisor to the National Autism Project; sits on the Autistica Discover Steering Committee; currently chairs the Autistica Physical Health and Ageing Research Group; and currently chairs the British Academy of Childhood Disability Strategic Research Group. He has not received payment for any of this activity. JP works for the UK NHS and sees children and young adults on the autism spectrum to give advice about diagnosis and treatments/interventions. JP runs research programs focused on autism from Newcastle University, and has received grants and published research papers in that context. JP is an author of a number of references cited in this topic.

Marc Woodbury-Smith, MB ChB, PhD, MRCPsych
Marc Woodbury-Smith

Clinical Senior Lecturer/Honorary Consultant

Biosciences Institute

Newcastle University

Newcastle upon Tyne

UK

Associate Investigator

Centre for Applied Genomics

Hospital for Sick Children

Toronto

Canada

Disclosures

MWS has received consultation fees from Servier Pharmaceuticals in connection with a clinical trial on which he was national co-ordinator (2018-2019). MWS is the co-author of references cited in this topic.

Peer reviewers

Robert Findling, MD, MBA

Chair

Department of Psychiatry

Virginia Commonwealth University

Richmond

VA

Disclosures

RF declares that he has acted as a consultant for, and/or has received honoraria or research support from the following: Acadia, Adamas, Aevi, Afecta, Akili, Alkermes, Allergan, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Arbor, Axsome, Daiichi-Sankyo, Emelex, Gedeon Richter, Genentech, Idorsia, Intra-Cellular Therapies, Kempharm, Luminopia, Lundbeck, MedAvante-ProPhase, Merck, MJH Life Sciences, NIH, Neurim, Otsuka, PaxMedica, PCORI, Pfizer, Physicians Postgraduate Press, Q BioMed, Receptor Life Sciences, Roche, Sage, Signant Health, Sunovion, Supernus Pharmaceuticals, Syneos, Syneurx, Takeda, Teva, Tris, and Validus.

Michael Absoud, FRCPCH, PhD

Consultant in Paediatric Neurodisability

Joint Head of Service

Children’s Neurosciences

Reader in Paediatric Neurosciences

Evelina London Children’s Hospital

Department of Women and Children’s Health

King’s College

London

UK

Disclosures

MA declares that he has no competing interests.

Grant Stewart, BA Hons

Consumer Health and Multimedia Manager

British Medical Journal (BMJ)

London

UK

Disclosures

GS declares that he is an employee of BMJ.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Levy SE, Mandell DS, Schultz RT. Autism. Lancet. 2009 Nov 7;374(9701):1627-38.Full text  Abstract

Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autistic spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006 Jul 15;368(9531):210-5. Abstract

Hyman SL, Levy SE, Myers SM, et al. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020 Jan;145(1):e20193447.Full text  Abstract

Anagnostou E, Zwaigenbaum L, Szatmari P, et al. Autism spectrum disorder: advances in evidence-based practice. CMAJ. 2014 Apr 15;186(7):509-19. Abstract

National Institute for Health and Care Excellence. Autism spectrum disorder in adults: diagnosis and management. June 2021 [internet publication].Full text

Baird G, Cass H, Slonims V. Diagnosis of autism. BMJ. 2003 Aug 30;327(7413):488-93.Full text  Abstract

Le Couteur A, Haden G, Hammal D, et al. Diagnosing autistic spectrum disorders in pre-school children using two standardised assessment instruments: the ADI-R and the ADOS. J Autism Dev Disord. 2008 Feb;38(2):362-72. Abstract

Parr J. Autism. BMJ Clin Evid. 2010 Jan 7;2010:0322.Full text

National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: support and management. June 2021 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Other causes of disordered development/learning difficulties/intellectual disability, or another neurodevelopmental disorder
    • ADHD
    • Social (pragmatic) communication disorder
    More Differentials
  • Guidelines

    • Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR)
    • Autism spectrum disorder in under 19s: support and management
    More Guidelines
  • Patient information

    Autism spectrum disorder: information for parents - What is autism spectrum disorder?

    Autism spectrum disorder: information for parents - Support strategies

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer